<html>
<head>
  <title>2D6</title>
<style>
  .td {font-family: "verdana"; font-size: "10px"; color: "navy";}
  .green {background-color:"#ACA899";font-family:verdana; font-size:8pt;}
  .lite {background-color:"#F1EFE2";font-family:verdana; font-size:8pt; color:"#666600";}
  A:link {COLOR: "navy"; text-decoration: none;}
  A:visited {COLOR: "navy"; text-decoration: none;}
  A:active {COLOR: "navy"; text-decoration: none;}
  A:hover {COLOR:"#66CCFF";}
  .normal {font-family: "verdana"; font-size: 10; color: "#000000";}
</style>
</head>

<body bgcolor="#FFFFFF" class="normal">
<CENTER>
<TABLE border="0" cellPadding="5" cellSpacing="5" width="90%" class="normal">
<tr><td>
<b>References for Cytochrome P450 Drug Interaction Table: 2C9</b><br><br>
	
These pages contain all the literature citations referenced in the Cytochrome P450 Drug Interaction Tables (both the extensive <a HREF="index.htm">research-oriented table</a> and the concise <a HREF="clinlist.htm"> clinical table</a>). Most of these citations are hyperlinks, which bring up the abstract in the NLM's PubMed database.
	
<p>Click on the [ PubMed ] link after the drug name to perform a live MedLINE search of articles possibly related to that drug and Cytochrome P450.</p>

<p>Entries are organized by mode of activity (substrate, inhibitor, inducer) within specific isoform. You can quickly branch to a section by clicking on the appropriate link here:</p>

<a href="1A2.htm">1A2</a> | <a href="2B6.htm">2B6</a> | <a href="2C8.htm">2C8</a> | <a href="2C19.htm">2C19</a> | 2C9 | <a href="2D6.htm">2D6</a> | <a href="2E1.htm">2E1</a> | <a href="3A457.htm">3A457</a>

<p>Use Ctrl-F to find all or part of the name or word for which you are searching.</p><br>

<hr color="#33CC66">
<hr color="#FF9900">
<p><h3><a name="3A457sub">2D6 SUBSTRATES</a></h3></p>
<hr color="#FF9900">
<hr color="#33CC66">

<p>
<a NAME="41alprenolol"><b>alprenolol:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+alprenolol&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Polymorphic drug oxidation in humans.</i><br>
Eichelbaum M<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=6714436&dopt=Abstract">Fed Proc 1984 May 15;43(8):2298-2302</a>
<p>
<i>Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.</i><br>
Otton SV, Inaba T, Kalow W<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=6141510&dopt=Abstract">Life
Sci 1984 Jan 2;34(1):73-80</a>
<p>
<a NAME="41amitriptyline"><b>amitriptyline:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+amitriptyline&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Amitriptyline metabolism: association with debrisoquin hydroxylation in
nonsmokers.</i><br>
Mellstrom B, Sawe J, Bertilsson L, Sjoqvist F<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=3956053&dopt=Abstract">Clin
Pharmacol Ther. 1986 Apr; 39(4): 369-371</a>
<p>
<i>Amitriptyline pharmacokinetics and clinical response: II. Metabolic
polymorphism assessed by hydroxylation of debrisoquine and
mephenytoin.</i><br>
Baumann P, Jonzier-Perey M, Koeb L, Kupfer A, Tinguely D, Schopf J<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=3571939&dopt=Abstract">Int
Clin Psychopharmacol. 1986 Apr; 1(2): 102-112</a>
<p>
<a name="41amphet"><b>amphetamine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+amphetamine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>The metabolic fate of amphetamine in man and other species.</i><br>
Dring LG, Smith RL, Williams TR<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=4985156&dopt=Abstract">Biochem
J 1970;425-435</a>
<p>
<i>Introduction: human genetic variations in oxidative drug
metabolism.</i><br>
Smith RL<br>
Xenobiotica 1986;16:361-365
<p>

<p><a name="41aripiprazole"><b>aripiprazole:</b></a> <i><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+aripiprazole&doptcmdl=DocSum">PubMed</a></i><br><br>
<i>Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.</i><br>
Swainston Harrison T, Perry CM.<br>
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15257633">Drugs. 2004;64(15):1715-36.</a>
</p>

<p>
<a name="41atomoxetine"><b>atomoxetine:</b></a> <i><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+atomoxetine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Identification of the human cytochromes P450 responsible for atomoxetine metabolism.</i><br>
Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA.<br>
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11854152&dopt=Abstract">Drug Metab Dispos. 2002 Mar;30(3):319-23.</a></p>
</p>

<p>
<a NAME="41bufuralol"><b>bufuralol:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=Search&DB=PubMed">PubMed</a></i>
<p>
<i>Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine
4-hydroxylase and bufuralol 1'-hydroxylase activities.</i><br>
Boobis AR, Murray S, Hampden CE, Davies DS<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=3966916&dopt=Abstract">Biochem
Pharmacol 1985 Jan 1;34(1):65-71</a>
<p>
<i>Characterization of a common genetic defect of cytochrome P-450 function
(debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant
(Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor
metabolizers.</i><br>
Dayer P, Gasser R, Gut J, Kronbach T, Robertz GM, Eichelbaum M, Meyer UA<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=6508804&dopt=Abstract">Biochem
Biophys Res Commun 1984 Nov 30;125(1):374-380</a>
<p>
<i>Debrisoquine-type polymorphism of drug oxidation: purification from human
liver of a cytochrome P450 isozyme with high activity for bufuralol
hydroxylation.</i><br>
Gut J, Gasser R, Dayer P, Kronbach T, Catin T, Meyer UA<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=6146537&dopt=Abstract">FEBS
Lett 1984 Aug 6;173(2):287-290</a>
<p>
<i>Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism
of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver
microsomes of in vivo phenotyped carriers of the genetic deficiency.</i><br>
Dayer P, Kronbach T, Eichelbaum M, Meyer UA<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=3689440&dopt=Abstract">Biochem
Pharmacol 1987 Dec 1;36(23):4145-4152</a>
<p>
<b><a NAME="41carvedilol">carvedilol:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+carvedilol&doptcmdl=DocSum">PubMed</a></i>
<p>
<b><a NAME="41chlorpheniramine">chlorpheniramine:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+chlorpheniramine&doptcmdl=DocSum">PubMed</a></i>
<p>
<b><a NAME="41chlorpromazine">chlorpromazine:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+substrate+AND+chlorpromazine&doptcmdl=DocSum">PubMed</a></i>
</p>


<b><a NAME="41clomipramine">clomipramine:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+clomipramine&doptcmdl=DocSum">PubMed</a></i>
<p>
<b><a NAME="41clomipramine"></a></b><i>Pharmacogenetics of antidepressants:
clinical aspects.</i><br>
Bertilsson L, Dahl ML, Tybring G<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9265947&dopt=Abstract">Acta
Psychiatr Scand Suppl 1997;391:14-21</a>
<p>
<a NAME="41codeine"><b>codeine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+codeine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Impact of environmental and genetic factors on codeine analgesia.</i><br>
Desmeules J, Gascon MP, Dayer P, Magistris M<i><br>
</i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1782973&dopt=Abstract">Eur
J Clin Pharmacol 1991;41(1):23-26</a>
<p>
<b><a NAME="41debrisoquine">debrisoquine:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+debrisoquine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Polymorphism of carbon oxidation of drugs and clinical
implications.</i><br>
Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=151576&dopt=Abstract">Br
Med J. 1978 Sep 2; 2(6138): 655-657</a>
<p>
<i>Genetically determined defects of oxidation at carbon centres of
drugs.</i><br>
Smith RL, Idle JR, Mahgoub AA, Sloan TP, Lancaster R<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=76883&dopt=Abstract">Lancet.
1978 Apr 29; 1(8070): 943-944</a>
<p>
<i>Hypotensive response to debrisoquine and hydroxylation phenotype.</i><br>
Idle JR, Mahgoub A, Lancaster R, Smith RL<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=642709&dopt=Abstract">Life
Sci. 1978 Mar; 22(11): 979-983</a>
<p>
<i>Polymorphic hydroxylation of Debrisoquine in man.</i><br>
Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=71400&dopt=Abstract">Lancet.
1977 Sep 17; 2(8038): 584-586</a>
<p>
<a name="41desipr"><b>desipramine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+desipramine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Polymorphic 2-hydroxylation of desipramine: A population and family
study.</i><br>
Dahl ML, Iselius L, Alm C, Svensson JO, Lee D, Johansson I. Ingelman-Sundberg
M. Sjoqvist F<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8359181&dopt=Abstract">Eur
J Clin Pharmacol 1993;44:445-450</a>
<p>
<a name="41dexfen"><b>dexfenfluramine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+dexfenfluramine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>The influence of the sparteine/debrisoquine genetic polymorphism on the
disposition of dexfenfluramine.</i><br>
Gross AS, Phillips AC, Rieutord A, Shenfield GM<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8730977&dopt=Abstract">Br
J Clin Pharmacol 1996;41:311-317</a>
<p>
<a NAME="41dextromethorphan"><b>dextromethorphan:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+dextromethorphan&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Debrisoquine and dextromethorphan phenotyping and antidepressant
treatment.</i><br>
Perault MC, Bouquet S, Bertschy G, Vandel S, Chakroun R, Guibert S, Vandel
B<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2020918&dopt=Abstract">Therapie
1991 Jan;46(1):1-3</a>

<p>
<a name="42doxepin"><b>doxepin</b></a>: 
<i><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+doxepin&doptcmdl=DocSum">PubMed</a></i><br>
<i>Doxepin inhibits CYP2D6 activity in vivo.</i><br>
Szewczuk-Boguslawska M, Kiejna A, Beszlej JA, Orzechowska-Juzwenko K, Milejski P<br>
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&dopt=Abstract&db=PubMed&list_uids=15520506">Pol J Pharmacol. 2004 Jul-Aug;56(4):491-4.</a>
</p>

<hr color="#33CC66">
<table class="normal">
<tr class="normal"><td width="125"><a name="41duloxetine"><b>&raquo;&nbsp;DULOXETINE</b></a></td>
<td>[ <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+duloxetine+AND+substrate&doptcmdl=DocSum">PubMed</a> ]</td></tr>
<tr class="normal"><td>Article</td><td>Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.</td></tr>
<tr class="normal"><td>Authors</td><td>Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12621382&dopt=Abstract">Clin Pharmacol Ther. 2003 Mar;73(3):170-7.</a></td></tr>
<tr class="normal"><td>Info</td><td><a href="http://www.rxlist.com/cgi/generic/cymbalta.htm">www.rxlist.com</a></td></tr>
</table>
<hr color="#33CC66">

<p>
<a NAME="41encainide"><b>encainide:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+encainide&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Effect of low dose quinidine on encainide pharmacokinetics and
pharmacodynamics. Influence of genetic polymorphism.</i><br>
Funck-Brentano C, Turgeon J, Woosley RL, Roden DM<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2496225&dopt=Abstract">J Pharmacol Exp Ther 1989 Apr;249(1):134-42</a>
<p>
<a NAME="41flecainide"><b>flecainide:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+flecainide&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Variable disposition kinetics and electrocardiographic effects of flecainide
during repeated dosing in humans: contribution of genetic factors, dose-dependent
clearance, and interaction with amiodarone.</i><br>
Funck-Brentano C, Becquemont L, Kroemer HK, Buhl K, Knebel NG, Eichelbaum
M, Jaillon P<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8143391&dopt=Abstract">Clin
Pharmacol Ther 1994 Mar;55(3):256-269 </a>
<p>
<a name="41fluoxe"><b>fluoxetine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+fluoxetine&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="41fluoxe"></a><i>The disposition of fluoxetine but not sertraline
is altered in poor metabolizers of debrisoquin.</i><br>
Hamelin BA, Turgeon J, Vallee F, Belanger P-M, Paquet F, LeBel M<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8941024&dopt=Abstract">Clin
Pharmacol Ther 1996;60:512-521</a>
<p>
<a name="41fluvox"><b>fluvoxamine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+fluvoxamine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Disposition of fluvoxamine in humans is determined by the polymorphic
CYP2D6 and also by the CYP1A2 activity.</i><br>
Carillo JA, Dahl M-L, Svennson J-O, Alm C, Rodriguez I, Bertillson L<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8823236&dopt=Abstract">Clin
Pharmacol Ther 1996;60:183-190</a>
</p>

<p><a name="histamineH1"><b>histamine H1 receptor antagonists</b></a>
<i><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+antihistamines&doptcmdl=DocSum">PubMed</a></i></p>
<p>
In Vitro Characterization of Cytochrome P450 2D6 Inhibition by Classic Histamine H1 Receptor Antagonists<br>
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9616188&dopt=Abstract">Drug Metab Dispos. 1998 Jun;26(6):536-9.</a>
</p>

<p>
<a name="41halope"><b>haloperidol:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+haloperidol&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Haloperidol disposition is dependent on the debrisoquine hydroxylation
phenotype: increased plasma levels of the reduced metabolite in poor
metabolizers.</i><br>
Llerena, A., Dahl, M.-L., Ekqvist, B., and Bertilsson, L<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1412613&dopt=Abstract">Ther
Drug Monit 14:261-264, 1992</a>
<p>
<a name="41imipra"><b>imipramine:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+imipramine&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="41imipra"></a><i>Role of P450 IID6, the target of the
sparteine-debrisoquin oxidation polymorphism, in the metabolism of
imipramine.</i><br>
Brøsen K, Zeugin T, Meyer UA<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2060250&dopt=Abstract">Clin
Pharmacol Ther 1991;49(6):609-617</a>
<p>
<a NAME="41lidocaine"><b>lidocaine:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+lidocaine&doptcmdl=DocSum">PubMed</a></i>
<p>
<a NAME="41metoclopramide"><b>metoclopramide:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+substrate+AND+metoclopramide&doptcmdl=DocSum">PubMed</a></i>
<p>
<a NAME="41methoxyamphetamine"><b>methoxyamphetamine:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+methoxyamphetamine&doptcmdl=DocSum">PubMed</a></i>
<p>
<a NAME="41metoprolol"><b>S-metoprolol:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+metoprolol&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on
the regio- and enantio-selective metabolism of metoprolol.</i><br>
Ellis SW, Rowland K, Ackland MJ, Rekka E, Simula AP, Lennard MS, Wolf CR,
Tucker GT<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8687412&dopt=Abstract">Biochem
J. 1996 Jun 1; 316( Pt 2): 647-654</a>
<p>
<i>Influence of debrisoquine oxidation phenotype on exercise tolerance and
subjective fatigue after metoprolol and atenolol in healthy subjects.</i><br>
Lewis RV, Ramsay LE, Jackson PR, Yeo WW, Lennard MS, Tucker GT<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2049246&dopt=Abstract">Br
J Clin Pharmacol 1991 Apr;31(4):391-398</a>
<p>
<i>Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor
pharmacodynamics of metoprolol and its enantiomers.</i><br>
Jonkers RE, Koopmans RP, Portier EJ, van Boxtel CJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1848636&dopt=Abstract">J
Pharmacol Exp Ther 1991 Mar;256(3):959-966</a>
<p>
<i>Debrisoquine polymorphism and the metabolism and action of metoprolol,
timolol, propranolol and atenolol.</i><br>
Lennard MS, Tucker GT, Silas JH, Woods HF<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2874665&dopt=Abstract">Xenobiotica
1986 May;16(5):435-447</a>
<p>
<i>Single-dose quinidine treatment inhibits metoprolol oxidation in extensive
metabolizers.</i><br>
Leemann T, Dayer P, Meyer UA<i><br>
</i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=3709620&dopt=Abstract">Eur
J Clin Pharmacol 1986;29(6):739-741</a>
<p>
<i>Metoprolol metabolism and debrisoquine oxidation polymorphism--population
and family studies.</i><br>
McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2868742&dopt=Abstract">Br
J Clin Pharmacol 1985 Dec;20(6):555-566</a>
<p>
<i>Differential stereoselective metabolism of metoprolol in extensive and
poor debrisoquin metabolizers.</i><br>
Lennard MS, Tucker GT, Silas JH, Freestone S, Ramsay LE, Woods HF<i><br>
</i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=6641087&dopt=Abstract">Clin
Pharmacol Ther 1983 Dec;34(6):732-737</a>
<p>
<i>Oxidation phenotype--a major determinant of metoprolol metabolism and
response.</i><br>
Lennard MS, Silas JH, Freestone S, Ramsay LE, Tucker GT, Woods HF<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7144837&dopt=Abstract">N
Engl J Med 1982 Dec 16;307(25):1558-1560</a>
<p>
<i>Defective metabolism of metoprolol in poor hydroxylators of
debrisoquine.</i><br>
Lennard MS, Silas JH, Freestone S, Trevethick J<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=6125207&dopt=Abstract">Br
J Clin Pharmacol 1982 Aug;14(2):301-303</a>
<p>
<b><a NAME="41mexillitene">mexiletine:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+mexiletine&doptcmdl=DocSum">PubMed</a></i>
</p>


<p>
<a name="41minapr"><b>minaprine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+minaprine&doptcmdl=DocSum">PubMed</a></i>
<i>Involvement of the cytochrome P-450IID subfamily in minaprine 4-hydroxylation
by human hepatic microsomes.</i><br>
Marre, F., Fabre, G., Lacarelle, B., Bourrie, M., Catalin, J., Berger, Y.,
Rahmani, R., and Cano, J.-P<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1352227&dopt=Abstract">Drug
Metab Dispos 20(2):316-321, 1992</a>

<p><b><a name="41nebivolol">nebivolol:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+nebivolol&doptcmdl=DocSum">PubMed</a></i><br><br>
<i>Pharmacokinetic disposition of nebivolol in extensive and poor CYP2D6 metabolizers.</i><br>
Andrew A. Shaw, John Ziemniak, Shiyao Liu, Scott W. Chervenick, Russell J. Rackley.<br>
American Society for Clinical Pharacology and Therapeutics.  March 2-6, 2005.  Orlando, FL.<br>

</p>


<p>
<b><a NAME="41nortriptyline">nortriptyline:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+nortriptyline&doptcmdl=DocSum">PubMed</a></i>
</p>

<p>
<b><a NAME="41oxycodone">oxycodone:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+oxycodone&doptcmdl=DocSum">PubMed</a></i>


<p>
<a name="41ondans"><b>ondansetron:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+ondansetron&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Disposition of fluvoxamine in humans is determined by the polymorphicCYP2D6 and also by the CYP1A2 activity.</i><br>
Carillo, J.A., Dahl, M.-L., Svennson, J., Rodriguez, I., and Bertilsson, L<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8823236&dopt=Abstract">Clin
Pharmacol Ther 60:183-190, 1996</a>





<p>
<b><a NAME="41paroxetine">paroxetine:</a></b>
<font COLOR="Blue"><i><u><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+paroxetine&doptcmdl=DocSum">PubMed</a></u></i></font>
<p>
<b><a NAME="41perhexiline">perhexiline:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+perhexiline&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="41perphe"><b>perphenazine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+perphenazine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Disposition of perphenazine is related to polymorphic debrisoquin
hydroxylation in human beings.</i><br>
Dahl-Puustinen, M.-L., Liden, A., Alm, C., Nordin, C., and Bertilsson, L<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2743709&dopt=Abstract">Clin
Pharmacol Ther 46(1):78-81, 1989</a>
<p>
<i>Steady state serum concentrations of the neuroleptic perphenazine in relation
to CYP2D6 genetic polymorphism.</i><br>
Linnet K, Wiborg O<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8689810&dopt=Abstract">Clin
Pharmacol Ther 1996;60:41-47</a>
<p>
<i>Inhibitors of imipramine metabolism by human liver microsomes.</i><br>
Skjelbo, E. and Brosen, K<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1389950&dopt=Abstract">Br
J Clin Pharmacol 34:256-261, 1992</a>
<p>
<b><a NAME="41phenacetin">phenacetin:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+phenacetin&doptcmdl=DocSum">PubMed</a></i>
<p>
<b><a NAME="41phenformin">phenformin:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+phenformin&doptcmdl=DocSum">PubMed</a></i>

<p><b><a name="41promethazine">promethazine</a></b>
<i><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+promethazine&doptcmdl=DocSum">PubMed</a></i></p>
<i>Akathisia with combined use of midodrine and promethazine.</i><br>
Platts SH, Shi SJ, Meck JV.<br>
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16670408&query_hl=3&itool=pubmed_DocSum">JAMA. 2006 May 3;295(17):2000-1.</a>


<p>
<a name="41propaf"><b>propafenone:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+propafenone&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>The role of genetically-determined polymorphic drug metabolism in the
beta-blockade produced by propafenone.</i><br>
Lee JT, Kroemer HK, Silberstein DJ, Funck-Brentano C, Lineberry MD, Wood
AJJ, Roden DM, Woosley RL<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1971708&dopt=Abstract">N
Eng J Med 1990;332(25):1764-1768</a>
<p>
<b><a NAME="41propanolol">propanolol:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+propanolol&doptcmdl=DocSum">PubMed</a></i>
<p>
<b><a NAME="41quanoxan">quanoxan:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+quanoxan&doptcmdl=DocSum">PubMed</a></i>
<p>
<a NAME="41risperidone"><b>risperidone:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+risperidone&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Pharmacokinetics of the novel antipsychotic agent risperidone and the
prolactin response in healthy subjects.</i><br>
Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA,
Zylicz Z, Visscher HW, Jonkman JH<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7690693&dopt=Abstract">Clin
Pharmacol Ther. 1993 Sep; 54(3): 257-268</a>
<p>
<a NAME="41sparteine"><b>sparteine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+sparteine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Pharmacogenetic covariation of defective N-oxidation of sparteine and
4-hydroxylation of debrisoquine.</i><br>
Bertilsson L, Dengler HJ, Eichelbaum M, Schulz HU<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7371707&dopt=Abstract">Eur
J Clin Pharmacol. 1980 Feb; 17(2): 153-155</a>
<p>
<i>Influence of the defective metabolism of sparteine on its
pharmacokinetics.</i><br>
Eichelbaum M, Spannbrucker N, Dengler HJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=499319&dopt=Abstract">Eur
J Clin Pharmacol. 1979 Sep; 16(3): 189-194</a>
<p>
<i>Defective N-oxidation of sparteine in man: a new pharmacogenetic
defect.</i><br>
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ<i><br>
</i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=499318&dopt=Abstract">Eur
J Clin Pharmacol. 1979 Sep; 16(3): 183-187</a>
<p>
<i>A human genetic defect in the metabolism of sparteine.</i><br>
Spannbrucker N, Eichelbaum M, Steinke B, Dengler HJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=741903&dopt=Abstract">Verh
Dtsch Ges Inn Med. 1978; 84: 1125-1127</a> German
<p>
<a name="31tamoxi"><b>tamoxifen:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+tamoxifen&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Delineation of human cytochromes P450 involved in the metabolism of
tamoxifen.</i><br>
Daniels, L., Blankson, E.A., Henderson, C.J., Harris, A.H., Wolf, C.R., Lennard,
M.S., and Tucker, G.T<br>
Br J Clin Pharmacol 33:153P, 1992
</p>

<p>
<i>Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.</i><br>
Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA.<br>
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14652237&dopt=Abstract">J Natl Cancer Inst. 2003 Dec 3;95(23):1734-5.</a><br>
</p>
<p>
<a name="41thiori"><b>thioridazine:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+thioridazine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Plasma levels of thioridazine and metabolites are influenced by the
debrisoquin hydroxylation phenotype.</i><br>
von Bahr C, Movin G, Nordon C, Liden A, Hammarlund-Udenaes,M, Hedberg,A,
Ring H, Sjoqvist F<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2007317&dopt=Abstract">Clin
Pharmacol Ther 49:234-240, 1991</a>
<p>
<a NAME="41timolol"><b>timolol:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+timolol&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Pharmacogenetic explanation for excessive beta-blockade following timolol
eye drops. Potential for oral-ophthalmic drug interaction.</i><br>
Edeki TI, He H, Wood AJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7474246&dopt=Abstract">JAMA.
1995 Nov 22; 274(20): 1611-1613</a>
<p>
<i>Systemic absorption of ocular timolol in poor and extensive metabolizers
of debrisoquine.</i><br>
Huupponen R, Kaila T, Lahdes K, Salminen L, Iisalo E<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1919275&dopt=Abstract">J
Ocul Pharmacol. 1991; 7(2): 183-187</a>
<p>
<i>The effects of timolol on intraocular pressure and exercise heart rate
in poor and extensive debrisoquine metabolizers.</i><br>
al-Sereiti MR, Edeki T, Lledo P, Turner P<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2099359&dopt=Abstract">Int
J Clin Pharmacol Res 1990;10(6):339-345</a>
<p>
<i>Prevalence of debrisoquine oxidation phenotypes in glaucoma
patients.</i><br>
Salminen L, Lindberg R, Toivari HR, Huupponen R, Kaila T, Iisalo E<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2787298&dopt=Abstract">Int
Ophthalmol 1989 Jan;13(1-2):91-93</a>
<p>
<i>Debrisoquine polymorphism and the metabolism and action of metoprolol,
timolol, propranolol and atenolol.</i><br>
Lennard MS, Tucker GT, Silas JH, Woods HF<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2874665&dopt=Abstract">Xenobiotica.
1986 May; 16(5): 435-447</a>
<p>
<i>Pharmacokinetics and beta-blocking effects of timolol in poor and extensive
metabolizers of debrisoquin.</i><br>
McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2864157&dopt=Abstract">Clin
Pharmacol Ther. 1985 Oct; 38(4): 409-413</a>
<p>
<i>Timolol and atenolol: relationships between oxidation phenotype,
pharmacokinetics and pharmacodynamics.</i><br>
Lewis RV, Lennard MS, Jackson PR, Tucker GT, Ramsay LE, Woods HF<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2859048&dopt=Abstract">Br
J Clin Pharmacol. 1985 Mar; 19(3): 329-333</a>
<p>
<i>Timolol determination in plasma and urine by high-performance liquid
chromatography with ultraviolet detection.</i><br>
Lennard MS, Parkin S<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=4019651&dopt=Abstract">J
Chromatogr. 1985 Feb 27; 338(1): 249-252</a>
<p>
<i>Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its
clinical relevance</i><br>
Smith RL<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=2865154&dopt=Abstract">Eur
J Clin Pharmacol. 1985; 28 Suppl: 77-84</a>

<p>
<a NAME="41tramadol"><b>tramadol:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+tramadol&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Pharmacology of tramadol.</i><br>
Dayer P, Desmeules J, Collart L<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=9190321&dopt=Abstract">Drugs 1997;53 Suppl 2:18-24</a><br><br>
<i>A rapid and simple CYP2D6 genotyping assay--case study with the analgetic tramadol.</i><br>
Borlak J, Hermann R, Erb K, Thum T.<br>
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14624403&dopt=Abstract">Metabolism. 2003 Nov;52(11):1439-43</a>
<p>
<a NAME="41venlafaxine"><b>venlafaxine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+venlafaxine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>O- and N-demethylation of venlafaxine in vitro by human liver microsomes
and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors
and SSRI antidepressants.<br>
</i>Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS,
Shader RI, Greenblatt DJ<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=10192828&dopt=Abstract">Neuropsychopharmacology
1999 May;20(5):480-90 </a>

<p><a name="41zuclopenthixol"><b>Zuclopenthixol: </b></a><i><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+venlafaxine&doptcmdl=DocSum">PubMed</a></i><br><br>
<i>Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?</i><br>
Dahl ML<br>
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=12083975&query_hl=2&itool=pubmed_docsum">Clin Pharmacokinet. 2002;41(7):453-70.</a><br><br>
<i>Pharmacogenetics of classical and new antipsychotic drugs.</i><br>
Otani K, Aoshima T<br>
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10688273&query_hl=2&itool=pubmed_docsum">Ther Drug Monit. 2000 Feb;22(1):118-21.</a>


</p>

<hr color="#33CC66">
<hr color="#FF9900">
<p><h3>2D6 INHIBITORS</h3></p>
<hr color="#FF9900">
<hr color="#33CC66">

<p>
<b><a NAME="42amiodarone">amiodarone:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+amiodarone&doptcmdl=DocSum">PubMed</a></i>
<p>
<b><a NAME="42bupropion">bupropion:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+bupropion&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Inhibition of CYP2D6 Activity by Bupropion.</i><br>
Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, Adson DE<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&dopt=Abstract&db=PubMed&list_uids=15876900">J Clin Psychopharmacol. 2005 Jun;25(3):226-229.</a></p>


<p>
<b><a NAME="42celecoxib">celecoxib:</a></b>
<i>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+celecoxib&doptcmdl=DocSum">PubMed</a></i>
<p>
<b><a NAME="42chlorpheniramine">chlorpheniramine:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+chlorpheniramine&doptcmdl=DocSum">PubMed</a></i>
<p>
<b><a NAME="42chlorprom">chlorpromazine:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+inhibitor+AND+chlorpromazine&doptcmdl=DocSum">PubMed</a></i>

<hr color="#33CC66">

<table class="normal">
<tr class="normal"><td width="125"><a name="cimetidine"><b>&raquo;&nbsp;CIMETIDINE</b></a></td>
<td>[ <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+cimetidine+AND+substrate&doptcmdl=DocSum">PubMed</a> ]</td></tr>
<tr class="normal"><td>Article</td><td>The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.</td></tr>
<tr class="normal"><td>Authors</td><td>Madeira M, Levine M, Chang TK, Mirfazaelian A, Bellward GD.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16680870&dopt=Abstract">Drug Metab Dispos. 2004 Apr;32(4):460-7.</a></td></tr>
<tr class="normal"><td>Info</td><td><a href="http://www.rxlist.com/cgi/generic/cimet.htm">www.rxlist.com</a></td></tr>
</table>
<hr color="#33CC66">



<p>
<i>Differential inhibition of individual human liver cytochromes P450 by cimetidine.</i><br>
Knodell RG, Browne DG, Gwozdz GP, Brian WR, Guengerich FP<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1955133&dopt=Abstract">Gastroenterology
1991;101:1680-1691</a></p>

<p>
<b><a name="42citalopram">citalopram:</a></b>
<i><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+substrate+AND+citalopram&doptcmdl=DocSum">PubMed</a></i></p>
<p>
<i>Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.</i><br>
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9068931">Clin Pharmacokinet. 1997;32 Suppl 1:1-21.</a>
</p>

<p>
<a NAME="42clomipramine"><b>clomipramine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+clomipramine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Cytochrome p450 IID6, its role in psychopharmacology.</i><br>
Lamard L, Perault MC, Bouquet S, Guibert S<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7741408&dopt=Abstract">Ann
Med Psychol (Paris) 1995 Feb;153(2):140-143</a>
<p>
<a name="42cocain"><b>cocaine:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+cocaine&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): Potent inhibition
of activity by (-)-cocaine and necleotide sequence identity to human hepatic
P450 gene CYP2D6.</i><br>
Tyndale RF, Sunahara RK, Inaba T, Kalow W, Gonzalez FJ, Niznik HB<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1857341&dopt=Abstract">Mol Pharmacol 40:63-68, 1991</a>
<p>
<a name="42doxoru"><b>doxorubicin:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+doxorubicin&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes.</i><br>
Le Guellec C, Lacarelle B, Catalin J, Durand A<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8258200&dopt=Abstract">Cancer Chemother Pharmacol 32:491-495, 1993</a></p>

<hr color="#33CC66">
<table class="normal">
<tr class="normal"><td width="125"><a name="duloxetine"><b>&raquo;&nbsp;DULOXETINE</b></a></td>
<td>[ <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+duloxetine+AND+substrate&doptcmdl=DocSum">PubMed</a> ]</td></tr>
<tr class="normal"><td>Article</td><td>Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.</td></tr>
<tr class="normal"><td>Authors</td><td>Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12621382&dopt=Abstract">Clin Pharmacol Ther. 2003 Mar;73(3):170-7.</a></td></tr>
<tr class="normal"><td>Info</td><td><a href="http://www.rxlist.com/cgi/generic/cymbalta.htm">www.rxlist.com</a></td></tr>
</table>
<hr color="#33CC66">


<p>
<b><a name="42escitalopram">escitalopram:</a></b>
<i><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+substrate+AND+escitalopram&doptcmdl=DocSum">PubMed</a></i>
</p>

<hr color="#33CC66">
<table class="normal">
<tr class="normal"><td width="125"><a name="42fluoxetine"><b>&raquo;&nbsp;FLUOXETINE</b></a></td>
<td>[ <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+fluoxetine+AND+substrate&doptcmdl=DocSum">PubMed</a> ]</td></tr>
<tr class="normal"><td>Article</td><td>Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.</td></tr>
<tr class="normal"><td>Authors</td><td>Brynne N, Svanström C, Aberg-Wistedt A, Hallén B, Bertilsson L.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10583026&dopt=Abstract">Br J Clin Pharmacol. 1999 Oct;48(4):553-63.</a><br><br></td></tr>

<tr class="normal"><td>Article</td><td>Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: prediction of in vivo drug interactions.</td></tr>
<tr class="normal"><td>Authors</td><td>Hara Y, Nakajima M, Miyamoto KI, Yokoi T.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16192107&dopt=Abstract"> Xenobiotica. 2005 Jun;35(6):549-60.</a><br><br></td></tr>

<tr class="normal"><td>Info</td><td><a href="http://www.rxlist.com/cgi/generic/fluoxetine.htm">www.rxlist.com</a></td></tr>
</table>
<hr color="#33CC66">




<p>
<b><a NAME="42halofantrine">halofantrine:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+halofantrine&doptcmdl=DocSum">PubMed</a></i>
<p>
<b><a NAME="42levomepromazine">levomepromazine:</a></b>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+levomepromazine&doptcmdl=DocSum">PubMed</a></i>

<p><b><a name="12midodrine">midodrine</a></b>
<i><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+midodrine&doptcmdl=DocSum">PubMed</a></i></p>
<i>Akathisia with combined use of midodrine and promethazine.</i><br>
Platts SH, Shi SJ, Meck JV.<br>
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16670408&query_hl=3&itool=pubmed_DocSum">JAMA. 2006 May 3;295(17):2000-1.</a>


<p>
<a NAME="42methadone"><b>methadone:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+methadone&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.</i><br>
Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, Sellers EM<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8448065&dopt=Abstract">Br
J Clin Pharmacol 1993 Jan;35(1):30-34</a>
<p>
<a name="42moclob"><b>moclobemide:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+moclobemide&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Moclobemide: a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6
and CYP1A2: A panel study.</i><br>
Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7781267&dopt=Abstract">Clin
Pharmacol Ther 1995;57(6):670-677</a>

<hr color="#33CC66">
<table class="normal">
<tr class="normal"><td width="125"><a name="42paroxe"><b>&raquo;&nbsp;PAROXETINE</b></a></td>
<td>[ <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+paroxetine+AND+substrate&doptcmdl=DocSum">PubMed</a> ]</td></tr>
<tr class="normal"><td>Article</td><td>Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.</td></tr>
<tr class="normal"><td>Authors</td><td>Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12584155&dopt=Abstract">Drug Metab Dispos. 2003 Mar;31(3):289-93.</a><br><br></td></tr>

<tr class="normal"><td>Article</td><td>CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.</td></tr>
<tr class="normal" valign="top"><td>Authors</td><td>Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15632378&dopt=Abstract">J Natl Cancer Inst. 2005 Jan 5;97(1):30-9.</a><br><br></td></tr>

<tr class="normal"><td>Article</td><td>Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.</td></tr>
<tr class="normal" valign="top"><td>Authors</td><td>Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14652237&dopt=Abstract">J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64.</a><br><br></td></tr>

<tr class="normal"><td>Article</td><td>Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.</td></tr>
<tr class="normal" valign="top"><td>Authors</td><td>Brosen K, Hansen JG, Nielsen KK, Sindrup SH, Gram LF.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8513845&dopt=Abstract">Eur J Clin Pharmacol 44:349-355, 1993.</a><br><br></td></tr>

<tr class="normal"><td>Article</td><td>Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline.</td></tr>
<tr class="normal" valign="top"><td>Authors</td><td>Spina E, Avenoso A, Salemi M, Facciolá G, Scordo MG, Ancione M, Madia A.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11147928&dopt=Abstract">Pharmacopsychiatry. 2000 Nov;33(6):213-7.</a><br><br></td></tr>

<tr class="normal" valign="top"><td>Article</td><td>CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.</td></tr>
<tr class="normal" valign="top"><td>Authors</td><td>Lam YW, Gaedigk A, Ereshefsky L, Alfaro CL, Simpson J.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12173784&dopt=Abstract">Pharmacotherapy. 2002 Aug;22(8):1001-6.</a><br><br></td></tr>

<tr class="normal"><td>Info</td><td><a href="http://www.rxlist.com/cgi/generic/parox.htm">www.rxlist.com</a></td></tr>
</table>
<hr color="#33CC66">

<table class="normal">
<tr class="normal"><td width="125"><a name="42quinidine"><b>&raquo;&nbsp;QUINIDINE</b></a></td>
<td>[ <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+quinidine+AND+substrate&doptcmdl=DocSum">PubMed</a> ]</td></tr>
<tr class="normal"><td>Article</td><td>Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding.</td></tr>
<tr class="normal"><td>Authors</td><td>McLaughlin LA, Paine MJ, Kemp CA, Maréchal JD, Flanagan JU, Ward CJ, Sutcliffe MJ, Roberts GC, Wolf CR.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16162505&dopt=Abstract">J Biol Chem. 2005 Nov 18;280(46):38617-24.</a><br><br></td></tr>

<tr class="normal"><td>Article</td><td>Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes.</td></tr>
<tr class="normal"><td>Authors</td><td>von Bahr C, Spina E, Birgersson C, Ericsson O, Göransson M, Henthorn T, Sjöqvist F.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4015690&dopt=Abstract">Biochem Pharmacol. 1985 Jul 15;34(14):2501-5.</a><br><br></td></tr>

<tr class="normal"><td>Article</td><td>In vivo modulation of CYP enzymes by quinidine and rifampin.</td></tr>
<tr class="normal"><td>Authors</td><td>Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11061580&dopt=Abstract">Clin Pharmacol Ther. 2000 Oct;68(4):401-11.</a><br><br></td></tr>

<tr class="normal"><td>Article</td><td>Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo.</td></tr>
<tr class="normal"><td>Authors</td><td>von Moltke LL, Greenblatt DJ, Duan SX, Daily JP, Harmatz JS, Shader RI.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9758674&dopt=Abstract">J Pharm Sci. 1998 Oct;87(10):1184-9.</a><br><br></td></tr>

<tr class="normal"><td>Info</td><td><a href="http://www.rxlist.com/cgi/generic/quinidex.htm">www.rxlist.com</a></td></tr>
</table>
<hr color="#33CC66">


<p>
<a NAME="42ranitidine"><b>ranitidine:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+ranitidine&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="42red-ha"><b>reduced haloperidol:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+haloperidol&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="42red-ha"></a><i>Oxidation of reduced haloperidol to haloperidol:
involvement of human P450 2D6.</i><br>
Tyndale RF, Kalow W, Inaba T<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=1867960&dopt=Abstract">Br
J Clin Pharmacol 1991;31:655-660</a>
<p>
<a name="42ritona"><b>ritonavir:</b></a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+ritonavir&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir
(ABT-538) in human liver microsomes.</i><br>
Kumar GN, Rodrigues AD, Buko AM, Denissen JF<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=8613951&dopt=Abstract">J
Pharmacol Exp Ther 1996;277(1):423-431</a>

<hr color="#33CC66">

<table class="normal">
<tr class="normal"><td width="125"><a name="sertraline"><b>&raquo;&nbsp;SERTRALINE</b></a></td>
<td>[ <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+sertraline+AND+substrate&doptcmdl=DocSum">PubMed</a> ]</td></tr>
<tr class="normal"><td>Article</td><td>The effect of sertraline on the pharmacokinetics of desipramine and imipramine.</td></tr>
<tr class="normal"><td>Authors</td><td>Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9284850&dopt=Abstract">Clin Pharmacol Ther. 1997 Aug;62(2):145-56.</a></td></tr>
<tr class="normal"><td>Info</td><td><a href="http://www.rxlist.com/cgi/generic/sertral.htm">www.rxlist.com</a></td></tr>
</table>
<hr color="#33CC66">

<table class="normal">
<tr class="normal"><td width="125"><a name="42terbinafine"><b>&raquo;&nbsp;TERBINAFINE</b></a></td>
<td>[ <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+terbinafine+AND+substrate&doptcmdl=DocSum">PubMed</a> ]</td></tr>
<tr class="normal"><td>Article</td><td>Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.</td></tr>
<tr class="normal"><td>Authors</td><td>Abdel-Rahman SM, Marcucci K, Boge T, Gotschall RR, Kearns GL, Leeder JS.</td></tr>
<tr class="normal" valign="top"><td>Link to Abstract</td><td><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10383919&dopt=Abstract">Drug Metab Dispos. 1999 Jul;27(7):770-5.</a></td></tr>
<tr class="normal"><td>Info</td><td><a href="http://www.rxlist.com/cgi/generic/terbin.htm">www.rxlist.com</a></td></tr>
</table>

<hr color="#33CC66">
<hr color="#FF9900">
<p><h3><a name="3A457sub">2D6 INDUCERS</a></h3></p>
<hr color="#FF9900">
<hr color="#33CC66">


<p>
<a NAME="43dexamethasone"><b>dexamethasone:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+dexamethasone&doptcmdl=DocSum">PubMed</a></i>
<p>
<a name="43rifamp"><b>rifampin:</b> </a>
<i><a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dispmax=20&db=PubMed&pmfilter_EDatLimit=No+Limit&cmd_current=Limits&orig_db=PubMed&cmd=Search&term=cytochrome+AND+p450+AND+rifampin&doptcmdl=DocSum">PubMed</a></i>
<p>
<i>The influence of enzyme induction on ploymorphic sparteine
oxidation.</i><br>
Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=3741726&dopt=Abstract">Br
J Clin Pharmacol 1986;22:49-53</a>
<p>
<i>The genetic polymorphism of sparteine metabolism.</i><br>
Eichelbaum M, Reetz K, Schmidt K, and Zekorn C<br>
<a HREF="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=3739368&dopt=Abstract">Xenobiotica
16(5):465-481, 1986</a>
</body></html>
